Skip to main navigation
Menu
  • Focus & Strategy
  • Innovation & Pipeline
  • Disease Areas
  • Investors & Media
  • Contact
Focus & Strategy
  • President’s Letter
  • Leadership
  • Board of Directors
Innovation & Pipeline
  • Roluperidone (MIN-101)
  • Seltorexant (MIN-202)
  • MIN-301
Disease Areas
  • Schizophrenia
  • Insomnia and Mood Disorders
  • Parkinson’s Disease
Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
Corporate Governance
  • Executive Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
Financials & Filings
  • SEC Filings
  • Annual Reports and Proxies
  • Quarterly Results
  • Key Ratios
Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Analyst Coverage
Minerva Neurosciences logo
  • Focus & Strategy
    • President’s Letter
    • Leadership
    • Board of Directors
  • Innovation & Pipeline
    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • Disease Areas
    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Contact

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS

Download Library

Date Document Type
September 11, 2014

Whistleblower Policy

Whistleblower Policy
May 16, 2014

Nominating Corporate Governance Committee Charter

Nominating Corporate Governance Committee Charter
May 16, 2014

Compensation Committee Charter

Compensation Committee Charter
May 16, 2014

Audit Committee Charter

Audit Committee Charter
May 16, 2014

Code of Ethics and Business Conduct

Code of Ethics and Business Conduct

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS
  • About Us

    • President's Letter
    • Leadership
    • Board of Directors
  • Disease Areas

    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Innovation & Pipeline

    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • (617) 600-7373
    email us
    Privacy Policy | Terms of Use

    ©2026 Minerva Neurosciences